Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
PLRX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Pliant Therapeutics, Inc.NASDAQ: PLRX
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $21.51M fell 63.5% year over year, behind the -49.4% change in trailing-twelve-month operating expenses. Sequentially, it fell 8.8% from the prior quarter. Over 3 fiscal years it compounded at +2.7% a year.
Context
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -63.5% toward the trailing-twelve-month pace of -49.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 148.38M USD
- Year-over-year change
- -35.0%
- 4-year CAGR
- +9.0%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 148.38M | -35.0% |
| FY2024 | 2024-12-31 | 228.37M | +23.0% |
| FY2023 | 2023-12-31 | 185.73M | +35.7% |
| FY2022 | 2022-12-31 | 136.89M | +30.2% |
| FY2021 | 2021-12-31 | 105.11M | — |
Operating Expenses vs competitors
How PLRX compares with its peers on the latest reported figures
- PLRX's LTM Mar 2026 operating expenses of $118.5M is the 5th highest of the 10 companies compared; the peer median is $92.88M.
- Its year-over-year change of -49.4% is the lowest of 10, against a peer median of -4.8%.
- Over three fiscal years its annual growth of +2.7% compares with a peer median of +2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $213.41M | -32.3% | +2.0% | 214.2% | |
| LTM Mar 2026 | $173.51M | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $144.89M | -39.4% | -12.4% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $122.7M | +143.6% | +40.1% | — |
| LTM Mar 2026 | $118.5M | -49.4% | +2.7% | — | |
| LTM Mar 2026 | $92.88M | -4.0% | +25.5% | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $91.4M | +21.9% | +10.8% | — |
| LTM Mar 2026 | $54.82M | -4.8% | -4.7% | 769.8% | |
| LTM Mar 2026 | $29.92M | +225.6% | +73.5% | 376.8% | |
| LTM Mar 2026 | $20.57M | -27.1% | -21.9% | 15353.0% | |
| Peer median (excluding PLRX) | $92.88M | -4.8% | +2.0% | 376.8% | |
Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.57M | 9.69M | 1.58M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.7M |
| Gross Profit | 7.57M | 9.69M | 1.58M | 0 | (1.7M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 77.55M | 96.94M | 127.8M | 169.31M | 109.16M |
| Selling, General & Admin | 27.56M | 39.95M | 57.93M | 59.06M | 47.22M |
| Operating Expenses | 105.11M | 136.89M | 185.73M | 228.37M | 148.38M |
| Depreciation & Amortization | 1.54M | 3.68M | 1.84M | 2.13M | 1.7M |
| EBITDA | (95.73M) | (118.85M) | (158.23M) | (205.16M) | (145.09M) |
| EBITDA Margin | -1264.2% | -1227.1% | -10014.4% | — | — |
| Operating Income | (97.54M) | (127.2M) | (184.15M) | (228.37M) | (150.07M) |
| Operating Margin | -1288.1% | -1313.4% | -11654.7% | — | — |
| Interest Income | 272K | 4.67M | 24.08M | 21.09M | 0 |
| Interest Expense | 0 | 791K | 1.27M | 3.02M | 2.56M |
| Other Income / Expenses | 272K | 3.88M | 22.81M | 18.06M | 729K |
| Income Before Tax | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Pre-Tax Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Net Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| EPS (Basic) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| EPS (Diluted) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| Weighted Avg Shares | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
| Weighted Avg Shares (Diluted) | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.